Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL852471 | 0.93 | MAPK1 (0.52) | MAPK1MEN1KMT2ACYP2D6OPRM1 | |
| SCHEMBL13177751 | 0.93 | MAPK1 (0.52) | MAPK1MEN1KMT2ACYP2D6OPRM1 | |
| SCHEMBL1849732 | 0.93 | MAPK1 (0.52) | MAPK1MEN1KMT2ACYP2D6OPRM1 | |
| SCHEMBL551494 | 0.93 | MAPK1 (0.52) | MAPK1MEN1KMT2ACYP2D6OPRM1 | |
| SCHEMBL13221771 | 0.93 | MAPK1 (0.58) | MAPK1MEN1KMT2ACYP2D6OPRM1 | |
| SCHEMBL15847688 | 0.93 | MAPK1 (0.58) | MAPK1MEN1KMT2ACYP2D6OPRM1 | |
| SCHEMBL3415585 | 0.92 | MAPK1 (0.48) | MAPK1MEN1KMT2A | |
| SCHEMBL853901 | 0.81 | MAPK1 (0.50) | MAPK1MEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL852564 | 0.81 | MAPK1 (0.55) | MAPK1MEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL15004475 | 0.81 | MAPK1 (0.55) | MAPK1MEN1KMT2AOPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183380-B2 | 2-aminoquinolines | HOFFMANN-LA ROCHE INC. (US) | 2012-05-22 | — | — | US | disclosed |
| EP-2262789-A1 | 2-AMINOQUINOLINES | F. Hoffmann-La Roche AG (CH) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009109477-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-11 | — | — | WO | disclosed |
| US-20090227570-A1 | 2-AMINOQUINOLINES | HOFFMANN-LA ROCHE, INC. | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227570-A1 | 2-AMINOQUINOLINES | HTR5A, HTR2C, HTR2A | MAPK1 3131/4885MEN1 1524/4885KMT2A 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.